Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks

Enliven Therapeutics, Inc.

Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.
ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.
89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.
Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.